Assessment of inflammatory markers and endothelial function

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 9, Issue 5, 2006, Pages 547-552

  Järvisalo, Mikko J ^c   Juonala, Markus ^a   Raitakari, Olli T ^b,d  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c SATAKUNTA CENTRAL HOSPITAL   (Finland)

^d NONE   (Finland)

Author keywords

Atherosclerosis; Endothelial function; Inflammation

Indexed keywords

ACUTE PHASE PROTEIN; AMYLOID A PROTEIN; AUTACOID; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; FIBRINOGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPROTEIN LIPASE; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC INFLAMMATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM INJURY; ENZYME LINKED IMMUNOSORBENT ASSAY; HELICOBACTER PYLORI; HUMAN; INFECTION; INFLAMMATION; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR ENDOTHELIUM;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; RISK ASSESSMENT; RISK FACTORS; VASCULAR DISEASES;

EID: 33747465854     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/01.mco.0000241663.00267.ae     Document Type: Review

References (34)

1. Puddu GM, Cravero E, Arnone G, et al. Molecular aspects of atherogenesis: new insights and unsolved questions. J Biomed Sci 2005; 12:839-853. •Comprehensive review article providing a summary of molecular changes observed in vascular diseases.
2. Langheinrich AC, Bohle RM. Atherosclerosis: humoral and cellular factors of inflammation. Virchows Arch 2005; 446:101-111. •Detailed review article describing recent experimental and human studies of inflammatory mechanisms underlying the pathogenesis of atherosclerosis.
3. Zernecke A, Weber C. Inflammatory mediators in atherosclerotic vascular disease. Basic Res Cardiol 2005; 100:93-101. •An excellent update on the inflammatory mediators in atherosclerosis.
4. Tobias P, Curtiss LK. Thematic review series. The immune system and atherogenesis: paying the price for pathogen protection: toll receptors in atherogenesis. J Lipid Res 2005; 46:404-411. •An overview of the role of toll-like receptors and their coactivators in atherosclerosis, with particular emphasis on studies in atherosclerosis-prone hypercholesterolemic mice.
5. Roberts WL. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to clinical and public health practice: laboratory tests available to assess inflammation - performance and standardization: a background paper. Circulation 2004; 110:e572-e576.
6. Modena MG, Bonetti L, Coppi F, et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002; 40:505-510.
7. Gokce N, Keaney JF Jr, Hunter LM, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003; 41:1769-1775.
8. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003; 108:2093-2098.
9. Huang AL, Vita JA. Effects of systemic inflammation on endothelium-dependent vasodilation. Trends Cardiovasc Med 2006; 16:15-20. •A review of experimental and clinical studies that support the relevance of inflammation to nitric oxide bioactivity in human atherosclerosis.
10. Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005; 46:937-954. ••An extensive updated overview of studies concerning the pathophysiology of atherothrombosis and plaque rupture.
11. Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101:2149-2153.
12. Skoog T, Dichtl W, Boquist S, et al. Plasma tumour necrosis factor-α and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 2002; 23:376-383.
13. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767-1772.
14. Myers GL, Rifai N, Tracy RP, et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the Laboratory Science Discussion Group. Circulation 2004; 110:e545-e549.
15. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279:1477-1482.
16. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387-1397.
17. Järvisalo MJ, Raitakari OT. Ultrasound assessment of endothelial function in children. Vascular Health and Risk Management 2005; 1:227-233.
18. Venugopal SK, Devaraj S, Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005; 14:33-37. •Review article focusing on the effects of CRP on different cells involved in atherosclerosis.
19. Devaraj S, Du Clos TW, Jialal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 2005; 25:1359-1363. •A carefully conducted experimental study demonstrating that CRP may mediate its biologic effects on human aortic endothelial cells via binding and internalization through Fcgamma receptors, CD32, and CD64.
20. Taylor KE, Giddings JC, van den BergCW. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 2005; 25:1225-1230. ••An interesting study presenting evidence that CRP per se does not activate endothelial cells. Instead, the artifacts caused by azide and lipopolysaccharide present in commercial CRP preparations seem to be responsible for the endothelial cell activation events observed in many previous studies.
21. Anand SX, Viles-Gonzalez JF, Badimon JJ, et al. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003; 90:377-384.
22. Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000; 343:1148-1155.
23. 2 and coronary endothelial function assessed by intracoronary acetylcholine infusion.
24. Juonala M, Viikari JS, Laitinen T, et al. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in Young Finns study. Circulation 2004; 110:2918-2923.
25. Benjamin EJ, Larson MG, Keyes MJ, et al. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 2004; 109:613-619.
26. Verma S, Wang CH, Lonn E, et al. Cross-sectional evaluation of brachial artery flow-mediated vasodilation and C-reactive protein in healthy individuals. Eur Heart J 2004; 25:1754-1760.
27. Ross R, Glomset J, Harker L. Response to injury and atherogenesis. Am J Pathol 1977; 86:675-684.
28. Järvisalo MJ, Raitakari M, Toikka JO, et al. Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation 2004; 109:1750-1755.
29. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52:402-411. •This study provided evidence that markers of systemic inflammation confer a statistically significant additional risk for cardiovascular death among patients with rheumatoid arthritis, even after controlling for traditional cardiovascular risk factors and comorbidities.
30. del Rincon I, Freeman GL, Haas RW, et al. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005; 52:3413-3423. •Study showing that both established cardiovascular risk factors and manifestations of rheumatoid arthritis inflammation contribute significantly to carotid atherosclerosis.
31. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349:2399-2406.
32. Sari I, Okan T, Akar S, et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006; 45:283-286. •A study demonstrating impairment of endothelial function in patients with ankylosing spondylitis.
33. Volanen I, Järvisalo MJ, Vainionpaa R, et al. Increased aortic intima-media thickness in 11-year-old healthy children with persistent Chlamydia pneumoniae seropositivity. Arterioscler Thromb Vasc Biol 2006; 26:649-655. •The relationship between C. pneumoniae infection and arterial measures of preclinical atherosclerosis has remained controversial. This study provides evidence in favor of the relationship, by demonstrating that children with persistent C. pneumoniae seropositivity have increased aortic intima-media thickness.
34. Corrado E, Rizzo M, Tantillo R, et al. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study. Stroke 2006; 37:482-486. •This study suggested that seropositivity for C. pneumoniae and for H. pylori were independently related to the occurrence of cerebrovascular and cardiovascular events in 5-year follow-up of adult patients with asymptomatic carotid lesions at baseline.